Background: Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease characterized by irreversible scarring of the lung parenchyma. Despite various interventions aimed at mitigating several different molecular aspects of the disease, only two drugs with limited clinical efficacy have so far been approved for IPF therapy. Objective: We investigated the therapeutic efficacy of amifostine, a detoxifying drug clinically used for radiation-caused cytotoxicity, in bleomycin-induced murine pulmonary fibrosis. Methods: C57BL6/J mice were intratracheally instilled with 3 U/kg of bleomycin. Three doses of amifostine (WR-2721, 200 mg/kg) were administered intraperitoneally on days 1, 3, and 5 after the bleomycin challenge. Bronchoalveolar lavage fluid (BALF) was collected on day 7 and day 21 for the assessment of lung inflammation, metabolites, and fibrotic injury. Human fibroblasts were treated in vitro with transforming growth factor beta 1 (TGF-β1), followed by amifostine (WR-1065, 1–4 µg/mL) treatment. The effects of TGF-β1 and amifostine on the mitochondrial production of reactive oxygen species (ROS) were assessed by live cell imaging of MitoSOX. Cellular metabolism was assessed by the extracellular acidification rate (ECAR), the oxygen consumption rate (OCR), and the concentrations of various energy-related metabolites as measured by mass spectrum (MS). Western blot analysis was performed to investigate the effect of amifostine on sirtuin 1 (SIRT1) and adenosine monophosphate activated kinase (AMPK). Results: Three doses of amifostine significantly attenuated lung inflammation and pulmonary fibrosis. Pretreatment and post-treatment of human fibroblast cells with amifostine blocked TGF-β1-induced mitochondrial ROS production and mitochondrial dysfunction in human fibroblast cells. Further, treatment of fibroblasts with TGF-β1 shifted energy metabolism away from mitochondrial oxidative phosphorylation (OXPHOS) and towards glycolysis, as observed by an altered metabolite profile including a decreased ratio of NAD + /NADH and increased lactate concentration. Treatment with amifostine significantly restored energy metabolism and activated SIRT1, which in turn activated AMPK. The activation of AMPK was required to mediate the effects of amifostine on mitochondrial homeostasis and pulmonary fibrosis. This study provides evidence that repurposing of the clinically used drug amifostine may have therapeutic applications for IPF treatment. Conclusion: Amifostine inhibits bleomycin-induced pulmonary fibrosis by restoring mitochondrial function and cellular metabolism.
We have shown that both reactive oxygen species (ROS) and paxillin tyrosine phosphorylation regulate LPS-induced human lung endothelial permeability. Mitochondrial ROS (mtROS) is known to increase endothelial cell (EC) permeability which requires dynamic change in mitochondrial morphology, events that are likely to be regulated by paxillin. Here, we investigated the role of paxillin and its tyrosine phosphorylation in regulating LPS-induced mitochondrial dynamics, mtROS production and human lung microvascular EC (HLMVEC) dysfunction. LPS, in a time-dependent manner, induced higher levels of ROS generation in the mitochondria compared to cytoplasm or nucleus. Down-regulation of paxillin expression with siRNA or ecto-expression of paxillin Y31F or Y118F mutant plasmids attenuated LPS-induced mtROS in HLMVECs. Pre-treatment with MitoTEMPO, a scavenger of mtROS, attenuated LPS-induced mtROS, endothelial permeability and VE-cadherin phosphorylation. Further, LPS-induced mitochondrial fission in HLMVECs was attenuated by both a paxillin siRNA, and paxillin Y31F/Y118F mutant. LPS stimulated phosphorylation of dynamin-related protein (DRP1) at S616, which was also attenuated by paxillin siRNA, and paxillinY31/Y118 mutants. Inhibition of DRP1 phosphorylation by P110 attenuated LPS-induced mtROS and endothelial permeability. LPS challenge of HLMVECs enhanced interaction between paxillin, ERK, and DRP1, and inhibition of ERK1/2 activation with PD98059 blocked mitochondrial fission. Taken together, these results suggest a key role for paxillin tyrosine phosphorylation in LPS-induced mitochondrial fission, mtROS generation and EC barrier dysfunction.
In osteoarthritis (OA) treatment, synovial mesenchymal stem cell-derived extracellular vesicles (SMSC-EVs) hold therapeutic potential; however, the mechanisms coordinating mitochondrial and epigenetic repair remain unclear. Chondrocyte proliferation, apoptosis and migration were assessed in vitro. Mitochondrial function was evaluated via membrane potential, oxygen consumption, ATP and reactive oxygen species (ROS) levels and network morphology. RNA sequencing and proteomics identified altered pathways. Key molecules (MFN2, S1PR1, GPS2, mTOR components) were investigated using siRNA knockdown. Protein localisation and interactions were examined by immunofluorescence, co-immunoprecipitation and in silico modelling. Efficacy was validated in a monosodium iodoacetate-induced rat OA model. SMSC-EVs enhanced chondrocyte proliferation, reduced apoptosis and restored mitochondrial fusion and bioenergetics through activation of the S1P-S1PR1-mTORC2 axis, leading to MFN2 upregulation (mean difference: 0.676 [95% CI: 0.572-0.778]). EV treatment also induced GPS2 nuclear translocation (mean difference: 0.403 for GPS2/lamin B [0.318-0.489]), facilitating interaction with HDAC1 and increased HDAC1 expression (mean difference: 0.474 [0.398-0.552]). In vivo, SMSC-EVs mitigated cartilage degradation and improved functional outcomes, reflected by decreased OARSI scores (mean difference: -9.000 [-10.518 to -7.482]). SMSC-EVs ameliorate OA through coordinated mitochondrial and epigenetic mechanisms, restoring mitochondrial integrity via the S1P-S1PR1-mTORC2-MFN2 pathway and promoting proliferation through GPS2-HDAC1-mediated epigenetic regulation. These findings highlight a synergistic therapeutic strategy targeting mitochondrial-epigenetic dysfunction in OA.